Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Valencene [4630-07-3]

Valencene [4630-07-3]

Imprimer Imprimer
Identifiez-vous

Référence HY-N6636-1mL

Conditionnement : 10mM/1mL

Marque : MedChemExpress


Description

Valencene is a sesquiterpene that can be isolated from Cyperus rotundus. Valencene possesses antiallergic, antimelanogenesis, anti-infammatory, and antioxidant activitivies. Valencene inhibits the exaggerated expression of Th2 chemokines and proinflammatory chemokines through blockade of the NF-κB pathway. Valencene inhibits the production and expression of proinflammatory cytokines IL-1β and IL-6 in LPS-stimulated RAW 264.7 cells. Valencene can reduce atopic dermatitis symptoms and recover decreased expression of filaggrin in DNCB-sensitized mouse model[1][2][3].

In Vitro

Valencene (10-100 μM, 1 h pre-treatment) significantly inhibits TNF-α/IFN-γ-stimulated chemokines secretion in HaCaT cells[1].
Valencene (10-100 μM, 24 h) significantly increases involucrin mRNA/protein expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Valencene Related Antibodies

RT-PCR[1]

Cell Line: TNF-α/IFN-γ-stimulated HaCaT cells
Concentration: 10, 50, 100 μM
Incubation Time: 1 h pre-treatment
Result: Significantly inhibited the mRNA expression of the AD-related chemokines CCL17/TARC. CCL22/MDC, CXCL8, MCP-1 and GM-CSF.
In Vivo

Valencene (200 μL of 0-100 μM, topical, three times a week for 10 weeks) significantly decreases the SCORAD index in DNCB-sensitized NC/Nga mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DNCB-sensitized male NC/Nga mice (6-week-old)[1]
Dosage: 200 μL of 0, 50 or 100 μM
Administration: Topical, three times a week for 10 weeks
Result: Resulted in increased expression of filaggrin.
Reduced stratching behavior.
Decreased the tissue levels of IL-1β, IL-6, and IL-13.
Markedly suppressed the DNCB-induced increase of IL-1β, IL-6, and IL-13 levels in spleen tissue.
Masse moléculaire

204.35

Formule

C15H24
CAS No.
Appearance

Liquid (Density: 0.92 g/cm3)

Color

Colorless to light yellow

SMILES

C=C([C@@H]1CCC2=CCC[C@@H](C)[C@]2(C)C1)C
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité
In Vitro: 

DMSO : 50 mg/mL (244.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8936 mL 24.4678 mL 48.9356 mL
5 mM 0.9787 mL 4.8936 mL 9.7871 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (12.23 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (12.23 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références